Medical Condition News

RSS

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Vision scientists identify an intricate process that allows the human eye to adapt quickly to darkness

Ever wonder how your eyes adjust during a blackout? When we go from light to near total darkness, cells in the retina must quickly adjust. Vision scientists at Washington University School of Medicine in St. Louis have identified an intricate process that allows the human eye to adapt to darkness very quickly. The same process also allows the eye to function in bright light.

14 Oct 2009

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

Doctors in Latvia have begun treatments using the region's first Novalis Tx(TM) radiosurgery platform from Varian Medical Systems and BrainLAB. Two prostate cancer patients have been treated using Varian's RapidArc® radiotherapy technology at the Riga Eastern Clinical University Hospital.

14 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Children with low birth weight are at a higher risk of developing asthma later in life, says study

A new study from the medical university Karolinska Institutet in Stockholm shows that children born with low birth weight are at a higher risk of developing asthma later in life. The study, which is published in the journal Pediatrics, is based on data on the incidence of asthma in 10,918 twins from the Swedish Twin Registry.

14 Oct 2009

HERO House granted 501 (c) (3) status by the Federal Government

HERO House, a consumer-driven advocacy and vocational center for persons suffering from severe mental illness, announced today, that it has become a free-standing not-for-profit agency and has been granted 501 (c) (3) status by the Federal Government designated as a public charity eligible to receive tax-deductible gifts and donations.

14 Oct 2009

MUC1 protein defends against the stomach ulcer bacterium, according to study

A special protein in the lining of the stomach has been shown to be an important part of the body's defense against the stomach ulcer bacterium Helicobacter pylori in a new study from the Sahlgrenska Academy at the University of Gothenburg. The discovery may explain why the bacterium makes some people more ill than others.

14 Oct 2009

NY Senators co-sponsors bill to establish comprehensive program for lung cancer

Today, Lung Cancer Alliance (LCA) hailed the support of Senators Chuck Schumer (D-NY) and Kirsten Gillibrand (D-NY) who have signed on as co-sponsors of a bill to establish the first ever multi-agency, comprehensive program targeted at lung cancer.

14 Oct 2009

Diabetes care undergoes a paradigm shift to delay onset of full-blown disease

Diabetes care is undergoing a paradigm shift in which insulin is being prescribed earlier, for more conditions, in order to delay the onset of full-blown disease, according to a study released today by Scientia Advisors.

14 Oct 2009

Renal artery stenosis does not necessitate surgical procedures

Some invasive procedures that are becoming increasingly common as a first line of treatment for patients diagnosed with narrowed arteries in and around the kidneys may not be necessary, according to a new study by researchers at Wake Forest University Baptist Medical Center.

14 Oct 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

Blocking newly discovered second molecular pathway may prevent angiogenesis: UCLA researchers

Researchers at the University of California Los Angeles (UCLA) have found that a second molecular pathway may need to be blocked to prevent malignant cells from creating new blood vessels [angiogenesis]. A study of patients with pancreatic cancer showed that CXCL5 may be a key molecule in the angiogenesis switch—the point at which cells stop being normal and start producing blood vessels that feed malignancy.

14 Oct 2009

Study: Animals are not essential for human cancer research

A recently released paper published in the journal Alternatives to Laboratory Animals (ATLA 37, 399-416), presents a serious challenge to long-standing claims that animals are an important part of human cancer research.

14 Oct 2009

2009 American Cancer Society Pathfinder in Palliative Care awarded to James A. Block

James A. Block, M.D., president of J.A. Block Health Associates, will receive the inaugural 2009 American Cancer Society Pathfinder in Palliative Care Award, which recognizes individuals who have demonstrated innovation and ingenuity in their contributions to the advancement of the field of palliative care.

14 Oct 2009

State-level education policy essential to reverse childhood obesity

The new issue of The State Education Standard, the journal of the National Association of State Boards of Education (NASBE), examines how education policymakers can best address childhood obesity in school settings.

14 Oct 2009

Survey shows etiology of current mastectomy rates is multifactorial

With there being a concern that mastectomy is excessively used as a treatment for breast cancer, a survey of nearly 2,000 women indicates that breast-conserving surgery was attempted as the initial therapy for about 75 percent of those surveyed, according to a study in the October 14 issue of JAMA, a theme issue on surgical care.

14 Oct 2009